治疗慢性 Pruritus:我们在突破的门吗?
Payton Smith1, Allison Kranyak1, Chandler E Johnson1
1Department of Dermatology, University of California at San Francisco, San Francisco, California, USA.
概括
新的皮肤治疗方法,包括生物药物和Janus激酶 (JAK) 抑制剂,对慢性有希望. 这些疗法针对神经通路,为15%受持续影响的人提供希望.
科学领域:
- 皮肤病学 皮肤病学
- 神经科学是一个神经科学.
背景情况:
- 慢性影响15%的人口,严重影响生活质量.
- 对于FDA批准的慢性治疗方法,有很大的未满足的需求.
- 目前的治疗方法,如镇静抗组胺药,对于非组胺诱导的,往往是无效的.
研究的目的:
- 审查关键研究和临床试验新的治疗方法.
- 突出治疗慢性,特别是结的进展.
- 讨论生物制剂和JAK抑制剂在食路径向中的潜力.
主要方法:
- 关键研究和临床试验的审查.
- 专注于prurigo nodularis病例,其中是主要的病理.
- 对治疗机制的分析,包括生物药物和JAK抑制剂.
主要成果:
- 杜皮卢马布在治疗结节炎的III期试验中显示出有效性.
- 简氏激酶 (JAK) 抑制剂在治疗慢性异常性方面取得了成功.
- 新疗法直接针对神经通路,不同于旧方法.
结论:
- 生物药物和JAK抑制剂代表了慢性管理的潜在突破.
- 这些新疗法通过作用于神经系统提供了有针对性的方法.
- 预计在治疗慢性方面将取得重大进展,解决一个主要的皮肤学未满足的需求.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
152
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
152
Psychosis: Goals of Pharmacotherapy
110
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
110
Drug Therapy
39
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
39
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
159
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
159
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98


